VITL Secures $7.5M Series A to Revolutionize E-Prescribing Amid GLP-1 Weight Loss Boom

Nashville-based startup VITL has landed $7.5 million in Series A funding led by SignalFire to upgrade its e-prescribing platform for booming cash-pay clinics.

The investment arrives as demand for GLP-1 drugs like Ozempic and Wegovy fuels explosive growth in med-spas, weight loss centers, and concierge practices.

GLP-1 Market Explosion and History

GLP-1 receptor agonists, first approved in 2005 for diabetes treatment, have transformed obesity care with significant weight loss outcomes.

Spending on these medications surged over 500% from 2018 to 2023, with the global market projected to hit $157 billion by 2035.

This boom has spawned tens of thousands of U.S. cash-pay clinics offering compounded versions and related treatments like peptides and Botox.

VITL's Platform Innovation

Founded by Charlie Jordan, the 18-month-old VITL connects clinics to a nationwide compounding pharmacy network with real-time price comparisons and order tracking.

The platform automates prescriptions, slashing processing time from minutes to seconds and saving providers up to two full workdays monthly.

In just over a year, VITL onboarded more than 630 clinics, achieving eight-figure annualized recurring revenue on pace for $10 million yearly.

Future Growth and Impact

Oral GLP-1 pills set to launch in 2026 will further accelerate demand for efficient prescribing tools in the expanding cash-pay sector.

Unlike general e-prescribing giants like Surescripts, VITL focuses solely on cash-pay workflows, differentiating from bundled EHR platforms.

SignalFire discovered VITL's traction via data analytics, underscoring the startup's organic momentum without a formal pitch.